title: All-comer treatment with bioresorbable vascular scaffold.
abstract: BACKGROUND
  Bioresorbable vascular scaffolds (BVS) could overcome drug-eluting stents (DES) drawbacks connected with their permanent presence in the vessel wall. Studies exploring the clinical use of BVS are limited to the patients presenting with noncomplex, short and stable lesions. There are no prospective and randomized studies available in all-comer patients.
  
  
  RESULTS
  We analyzed 31 patients, who received at least one BVS (Absorb(™)) between September 1, 2012 and November 1, 2014. Median follow-up period was 424 days. In one (3.2%) patient, we performed a target vessel revascularization (TVR). The death rate was 6.5%. One (3.2%) patient, who received both BVS and a bare metal stent (BMS), died of an acute stent thrombosis 8 days after the initial procedure. One (3.2%) patient died of a non-cardiac death. We did not encounter any target lesion revascularization (TLR) or myocardial infarction (MI). The major adverse cardiac events (MACE) rate was 3.2%.
  
  
  CONCLUSIONS
  Implantation of BVS is a safe treatment option. Lesions should be carefully selected and prepared before BVS implantation. We need more data about the safety of BVS and BMS overlapping.
authors.affiliation: Department for Cardiology, University Medical Centre Ljubljana, Gubčeve brigade 11, SI-1000, Ljubljana, Slovenia.
authors.forename: Matjaž
authors.initials: M
authors.lastname: Bunc
authors.affiliation: Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
authors.forename: Miha
authors.initials: M
authors.lastname: Mrak
authors.affiliation: Department for Cardiology, University Medical Centre Ljubljana, Gubčeve brigade 11, SI-1000, Ljubljana, Slovenia. peter.rakovec@telemach.net.
authors.forename: Peter
authors.initials: P
authors.lastname: Rakovec
mesh_terms: D020341:Absorbable Implants; D054058:Acute Coronary Syndrome / Q000175:diagnosis* / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D006801:Humans; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D012189:Retrospective Studies; D054457:Tissue Scaffolds; D016896:Treatment Outcome
keywords: Acute coronary syndrome; All-comer; Bioresorbable vascular scaffold; IVUS; Stent thrombosis
references.citation: JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197
references.pmid: 25616924
references.citation: Eur Heart J. 2012 Jan;33(1):16-25b
references.pmid: 22041548
references.citation: Lancet. 2009 Mar 14;373(9667):897-910
references.pmid: 19286089
references.citation: JACC Cardiovasc Interv. 2014 Jan;7(1):81-8
references.pmid: 24332424
references.citation: JACC Cardiovasc Interv. 2013 Oct;6(10 ):999-1009
references.pmid: 24156961
references.citation: Lancet. 2015 Jan 3;385(9962):43-54
references.pmid: 25230593
references.citation: J Am Coll Cardiol. 2014 Dec 16;64(23 ):2541-51
references.pmid: 25500240
references.citation: JACC Cardiovasc Interv. 2014 Sep;7(9):1070-2
references.pmid: 25234682
references.citation: Can J Cardiol. 2015 Mar;31(3):255-9
references.pmid: 25660152
references.citation: EuroIntervention. 2014 Jan 22;9(9):1036-41
references.pmid: 23999237
references.citation: J Cardiovasc Med (Hagerstown). 2015 Mar;16(3):178-88
references.pmid: 24978874
references.citation: EuroIntervention. 2015 Feb;10(10):1144-53
references.pmid: 25042421
references.citation: Int J Cardiol. 2015 Jan 20;179:90-4
references.pmid: 25464422
references.citation: Pol Arch Med Wewn. 2014;124(12 ):669-77
references.pmid: 25563622
references.citation: Eur Heart J. 2014 Oct 1;35(37):2541-619
references.pmid: 25173339
references.citation: Minerva Cardioangiol. 2013 Jun;61(3):255-62
references.pmid: 23681128